As February begins, major U.S. stock indexes have shown a strong start, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. In this context of market optimism ...

Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific scrutiny ...

The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., July 23, 2025 /PRNewswire/ -- According to MarketsandMarkets(TM), The modified cassava starch ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year Cassava Sciences Inc.'s stock tumbled 85% Monday to put ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show ...

Cassava Sciences' shares fell sharply Tuesday morning after the company said it would discontinue the development of its Alzheimer's treatment after recent trials didn't meet any of their objectives.

Cassava, also known as yuca or manioc, was once known mostly in Caribbean, African, and South American cuisines — but has grown in popularity, popping up as an ingredient in countless gluten-free and ...